Our site is slower due to heavy traffic from automated ’bots’ and AI crawlers. We’re working to fix this. Read more here.

Phillipp Hartmann

Title(s)Assistant Adjunct Professor, Pediatrics
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
ORCID ORCID Icon0000-0003-3658-3335 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of Regensburg, Regensburg, GermanyMD11/2013Medicine
    University of California San Diego, La Jolla, CAPostdoctoral06/2016Gastroenterology
    University of California San Diego, La Jolla, CAResident06/2019Pediatrics
    University of California San Diego, La Jolla, CAFellow07/2022Pediatric Gastroenterology
    University of California San Diego, La Jolla, CAMAS06/2023Clinical Research

    Collapse Overview 
    Collapse overview
    Dr. Hartmann is an Assistant Professor in Pediatrics at the University of California San Diego and is interested in the role of the intestinal microbiome in various liver diseases, including pediatric metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), as well as obesity. He aims to develop novel diagnostic and therapeutic strategies that will help to design more personalized treatment approaches.

    Collapse Research 
    Collapse research activities and funding
    NIH/UCSD Altman Clinical and Translational Research Institute (ACTRI) KL2TR001444May 1, 2023 - Apr 30, 2026
    Role: Principal Investigator
    Role of Candida albicans for the development of non-alcoholic steatohepatitis
    American Association for the Study of Liver Diseases (AASLD), Pinnacle Award PNC22-159963Jul 1, 2022 - Jun 30, 2025
    Role: Principal Investigator
    Intestinal Mycobiome in Pediatric Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
    NIH/NICHD K12HD000850-36Jul 1, 2020 - Jun 30, 2023
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. mAChR4 suppresses liver disease via GAP-induced antimicrobial immunity. Nature. 2025 Aug 20. Llorente C, Raya Tonetti F, Bruellman R, Brea R, Pell N, Hartmann P, Maccioni L, Han H, Cabré N, Liu J, Eguileor A, Fondevila MF, Meijnikman AS, Hsu CL, Alghafri A, Zhou R, Gao B, Duan Y, Zhang P, Febbraio MA, Taniguchi K, Newberry RD, Fouts DE, Brenner DA, Stärkel P, Karin M, Schnabl B. PMID: 40836099.
      View in: PubMed   Mentions:    Fields:    
    2. Gut microbiome-specific nanoparticle-based therapeutics for liver diseases. World J Gastroenterol. 2025 Jul 21; 31(27):109105. Khurana A, Hartmann P. PMID: 40741099; PMCID: PMC12305154.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    3. Prevalence of Extremely Severe Obesity and Metabolic Dysfunction Among US Children and Adolescents. JAMA Netw Open. 2025 07 01; 8(7):e2521170. Münte E, Zhang X, Khurana A, Hartmann P. PMID: 40668581; PMCID: PMC12268495.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Call to action-Pediatric MASLD requires immediate attention to curb health crisis. Hepatology. 2025 Jun 23. Hartmann P, Mouzaki M, Hassan S, Kehar M, Mysore KR, Mauney E, Nonga D, Karjoo S, Sood S, Tou A, Brichta C, Herdes RE, Pai N, Garner DK, Rinella ME, Noureddin M, Younossi Z, Allen AM, Sanyal A, Kohut T, Kohli R, Ramirez CM, Xanthakos S, Vos MB, Schwimmer JB, Ibrahim SH, Panganiban J. PMID: 40550108; PMCID: PMC12236211.
      View in: PubMed   Mentions: 1     Fields:    
    5. Impact of Gut Microbiome on Gut Permeability in Liver and Gut Diseases. Microorganisms. 2025 May 23; 13(6). Saha P, Hartmann P. PMID: 40572077; PMCID: PMC12195470.
      View in: PubMed   Mentions:
    6. Antiobesity medications in adult and pediatric obesity and metabolic dysfunction-associated steatotic liver disease. Pharmacol Rev. 2025 Jul; 77(4):100058. Rodriguez N, Hartmann P. PMID: 40554267.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    7. The Role of Short-Chain Fatty Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease and Other Metabolic Diseases. Biomolecules. 2025 Mar 22; 15(4). Münte E, Hartmann P. PMID: 40305160; PMCID: PMC12025087.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    8. Faecalibacterium prausnitzii Is Associated with Disease Severity in MASLD but Its Supplementation Does Not Improve Diet-Induced Steatohepatitis in Mice. Microorganisms. 2025 Mar 18; 13(3). Münte E, Viebahn G, Khurana A, Fujiki J, Nakamura T, Lang S, Demir M, Schnabl B, Hartmann P. PMID: 40142567; PMCID: PMC11944644.
      View in: PubMed   Mentions: 3  
    9. d4-Cystamine: A Deuterated Cystamine Derivative with Improved Anti-Inflammatory and Anti-Fibrotic Activities in a Murine Model of Fibrosing Steatohepatitis. ACS Pharmacol Transl Sci. 2025 Mar 14; 8(3):885-898. Leszczynska A, Alle T, Kaufmann B, Sung H, Stoess C, Reca A, Kim A, Kim S, Tran C, Oukoloff K, Monti L, Lucero B, Gertsman I, Momper JD, Hartmann P, Feldstein AE, Dohil R, Ballatore C. PMID: 40109735; PMCID: PMC11915185.
      View in: PubMed   Mentions:
    10. Faecal proteomics links neutrophil degranulation with mortality in patients with alcohol-associated hepatitis. Gut. 2024 Dec 10; 74(1):103-115. Kreimeyer H, Gonzalez CG, Fondevila MF, Hsu CL, Hartmann P, Zhang X, Stärkel P, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Investigators A, Gonzalez DJ, Schnabl B. PMID: 39033024; PMCID: PMC11631684.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    11. Fecal gelatinase does not predict mortality in patients with alcohol-associated hepatitis. Microb Cell. 2024; 11:328-338. Yang Y, Hartmann P, Schnabl B. PMID: 39206205; PMCID: PMC11350238.
      View in: PubMed   Mentions:
    12. Do Glucagon-like Peptide 1 Receptor Agonists Cause Postendoscopic Aspiration Pneumonia? Gastroenterology. 2025 Jan; 168(1):180-181. Hartmann P. PMID: 38580130.
      View in: PubMed   Mentions: 1     Fields:    
    13. Collagenous gastritis with elevated fecal calprotectin in a pediatric patient. JPGN Rep. 2024 May; 5(2):152-157. Rodriguez N, Kumar S, Mo J, Hartmann P. PMID: 38756119; PMCID: PMC11093908.
      View in: PubMed   Mentions: 1  
    14. Serum aryl hydrocarbon receptor activity is associated with survival in patients with alcohol-associated hepatitis. Hepatology. 2024 08 01; 80(2):403-417. Yamazaki T, Kouno T, Hsu CL, Hartmann P, Mayo S, Zhang X, Stärkel P, Bosques-Padilla F, Verna EC, Abraldes JG, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross DL, Louvet A, Lucey MR, Mathurin P, Garcia-Tsao G, Bataller R, Schnabl B, AlcHepNet Investigators. PMID: 38377466; PMCID: PMC11268475.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    15. Fungal signature differentiates alcohol-associated liver disease from nonalcoholic fatty liver disease. Gut Microbes. 2024 Jan-Dec; 16(1):2307586. Viebahn G, Hartmann P, Lang S, Demir M, Zhang X, Fouts DE, Stärkel P, Schnabl B. PMID: 38298161; PMCID: PMC10841010.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    16. How to calculate sample size in animal and human studies. Front Med (Lausanne). 2023; 10:1215927. Zhang X, Hartmann P. PMID: 37663663; PMCID: PMC10469945.
      View in: PubMed   Mentions: 18  
    17. Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease. World J Hepatol. 2023 May 27; 15(5):609-640. Jayasekera D, Hartmann P. PMID: 37305367; PMCID: PMC10251277.
      View in: PubMed   Mentions: 7  
    18. Fecal cytolysin does not predict disease severity in acutely decompensated cirrhosis and acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int. 2023 Oct; 22(5):474-481. Hartmann P, Lang S, Schierwagen R, Klein S, Praktiknjo M, Trebicka J, Schnabl B. PMID: 37198098; PMCID: PMC10797562.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    19. Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease. Am J Physiol Gastrointest Liver Physiol. 2023 07 01; 325(1):G42-G61. Kaufmann B, Seyfried N, Hartmann D, Hartmann P. PMID: 37129252; PMCID: PMC10312326.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    20. Global and national prevalence of nonalcoholic fatty liver disease in adolescents: An analysis of the global burden of disease study 2019. Hepatology. 2023 10 01; 78(4):1168-1181. Hartmann P, Zhang X, Loomba R, Schnabl B. PMID: 37021791; PMCID: PMC10521800.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    21. Engineered bacteria producing aryl-hydrocarbon receptor agonists protect against ethanol-induced liver disease in mice. Alcohol Clin Exp Res (Hoboken). 2023 May; 47(5):856-867. Kouno T, Zeng S, Wang Y, Duan Y, Lang S, Gao B, Hartmann P, Cabré N, Llorente C, Galbert C, Emond P, Sokol H, James M, Chao CC, Gao JR, Perreault M, Hava DL, Schnabl B. PMID: 36871955; PMCID: PMC10795770.
      View in: PubMed   Mentions: 16     Fields:    
    22. Candida albicans-specific Th17 cell-mediated response contributes to alcohol-associated liver disease. Cell Host Microbe. 2023 03 08; 31(3):389-404.e7. Zeng S, Rosati E, Saggau C, Messner B, Chu H, Duan Y, Hartmann P, Wang Y, Ma S, Huang WJM, Lee J, Lee SM, Carvalho-Gontijo R, Zhang V, Hoffmann JP, Kolls JK, Raz E, Brenner DA, Kisseleva T, LeibundGut-Landmann S, Bacher P, Stärkel P, Schnabl B. PMID: 36893735; PMCID: PMC10039706.
      View in: PubMed   Mentions: 23     Fields:    Translation:AnimalsCells
    23. IgY antibodies against cytolysin reduce ethanol-induced liver disease in mice. Hepatology. 2023 07 01; 78(1):295-306. Cabré N, Hartmann P, Llorente C, Kouno T, Wang Y, Zeng S, Kim HY, Zhang X, Kisseleva T, Iyer S, Kudumala S, Schnabl B. PMID: 36811393; PMCID: PMC10293100.
      View in: PubMed   Mentions: 7     Fields:    Translation:Animals
    24. Differences in Bacterial Translocation and Liver Injury in Ethanol Versus Diet-Induced Liver Disease. Dig Dis Sci. 2023 07; 68(7):3059-3069. Hsu CL, Wang Y, Duan Y, Chu H, Hartmann P, Llorente C, Zhou R, Schnabl B. PMID: 36807831; PMCID: PMC10313731.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    25. Malassezia restricta promotes alcohol-induced liver injury. Hepatol Commun. 2023 02 01; 7(2):e0029. Zeng S, Hartmann P, Park M, Duan Y, Lang S, Llorente C, Wang Y, Cabré N, Fouts DE, Bacher P, Jung WH, Stärkel P, Schnabl B. PMID: 36706195; PMCID: PMC9988279.
      View in: PubMed   Mentions: 12     Fields:    Translation:Animals
    26. Can a mucosal microbiota signature predict disease severity, survival, and disease recurrence in PSC? Hepatology. 2023 03 01; 77(3):709-711. Hartmann P, Schnabl B. PMID: 36626635.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Fungal infections and the fungal microbiome in hepatobiliary disorders. J Hepatol. 2023 04; 78(4):836-851. Hartmann P, Schnabl B. PMID: 36565724; PMCID: PMC10033447.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimals
    28. A critical review of recent knowledge of alcohol's effects on the immunological response in different tissues. Alcohol Clin Exp Res (Hoboken). 2023 01; 47(1):36-44. Crotty K, Anton P, Coleman LG, Morris NL, Lewis SA, Samuelson DR, McMahan RH, Hartmann P, Kim A, Ratna A, Mandrekar P, Wyatt TA, Choudhry MA, Kovacs EJ, McCullough R, Yeligar SM. PMID: 36446606; PMCID: PMC9974783.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    29. Inexpensive, Accurate, and Stable Method to Quantitate Blood Alanine Aminotransferase (ALT) Levels. Methods Protoc. 2022 Oct 14; 5(5). Hartmann P, Schnabl B. PMID: 36287053; PMCID: PMC9610295.
      View in: PubMed   Mentions: 3  
    30. Liver cirrhosis and immune dysfunction. Int Immunol. 2022 09 06; 34(9):455-466. Hasa E, Hartmann P, Schnabl B. PMID: 35792761; PMCID: PMC9447994.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    31. Editorial: The Microbiome in Hepatobiliary and Intestinal Disease. Front Physiol. 2022; 13:893074. Hartmann P. PMID: 35492588; PMCID: PMC9044070.
      View in: PubMed   Mentions: 6  
    32. Intestinal virome in patients with alcohol use disorder and after abstinence. Hepatol Commun. 2022 08; 6(8):2058-2069. Hsu CL, Zhang X, Jiang L, Lang S, Hartmann P, Pride D, Fouts DE, Stärkel P, Schnabl B. PMID: 35368152; PMCID: PMC9315129.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    33. Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice. Hepatol Int. 2022 Apr; 16(2):359-370. Hartmann P, Duan Y, Miyamoto Y, Demir M, Lang S, Hasa E, Stern P, Yamashita D, Conrad M, Eckmann L, Schnabl B. PMID: 35075592; PMCID: PMC9013343.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimals
    34. The fecal mycobiome in non-alcoholic fatty liver disease. J Hepatol. 2022 04; 76(4):788-799. Demir M, Lang S, Hartmann P, Duan Y, Martin A, Miyamoto Y, Bondareva M, Zhang X, Wang Y, Kasper P, Bang C, Roderburg C, Tacke F, Steffen HM, Goeser T, Kruglov A, Eckmann L, Stärkel P, Fouts DE, Schnabl B. PMID: 34896404; PMCID: PMC8981795.
      View in: PubMed   Mentions: 87     Fields:    Translation:HumansAnimals
    35. Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases. Hepatology. 2022 01; 75(1):219-228. Ginès P, Castera L, Lammert F, Graupera I, Serra-Burriel M, Allen AM, Wong VW, Hartmann P, Thiele M, Caballeria L, de Knegt RJ, Grgurevic I, Augustin S, Tsochatzis EA, Schattenberg JM, Guha IN, Martini A, Morillas RM, Garcia-Retortillo M, de Koning HJ, Fabrellas N, Pich J, Ma AT, Diaz MA, Roulot D, Newsome PN, Manns M, Kamath PS, Krag A, LiverScreen Consortium Investigators. PMID: 34537988.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansPHPublic Health
    36. Dynamic Changes of the Fungal Microbiome in Alcohol Use Disorder. Front Physiol. 2021; 12:699253. Hartmann P, Lang S, Zeng S, Duan Y, Zhang X, Wang Y, Bondareva M, Kruglov A, Fouts DE, Stärkel P, Schnabl B. PMID: 34349667; PMCID: PMC8327211.
      View in: PubMed   Mentions: 48  
    37. Complete Absence of the Extrahepatic Biliary Tree in a Newborn With Pigmented Stools. Pediatrics. 2021 07; 148(1). Hartmann P, Carter R, Keller B, Saenz NC, Schwarz KB. PMID: 34398808.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. Semin Liver Dis. 2021 01; 41(1):87-102. Hartmann P, Schnabl B. PMID: 33957682; PMCID: PMC8163568.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    39. Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either. Am J Physiol Gastrointest Liver Physiol. 2019 05 01; 316(5):G563-G573. Hartmann P, Chu H, Duan Y, Schnabl B. PMID: 30767680; PMCID: PMC6580239.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimals
    40. Reply to: "Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot? J Hepatol. 2018 12; 69(6):1400-1401. Brandl K, Hartmann P, Jih LJ, Pizzo DP, Schnabl B. PMID: 30301625.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    41. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. Hepatology. 2018 06; 67(6):2150-2166. Hartmann P, Hochrath K, Horvath A, Chen P, Seebauer CT, Llorente C, Wang L, Alnouti Y, Fouts DE, Stärkel P, Loomba R, Coulter S, Liddle C, Yu RT, Ling L, Rossi SJ, DePaoli AM, Downes M, Evans RM, Brenner DA, Schnabl B. PMID: 29159825; PMCID: PMC5962369.
      View in: PubMed   Mentions: 146     Fields:    Translation:Animals
    42. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol. 2018 08; 69(2):396-405. Brandl K, Hartmann P, Jih LJ, Pizzo DP, Argemi J, Ventura-Cots M, Coulter S, Liddle C, Ling L, Rossi SJ, DePaoli AM, Loomba R, Mehal WZ, Fouts DE, Lucey MR, Bosques-Padilla F, Mathurin P, Louvet A, Garcia-Tsao G, Verna EC, Abraldes JG, Brown RS, Vargas V, Altamirano J, Caballería J, Shawcross D, Stärkel P, Ho SB, Bataller R, Schnabl B. PMID: 29654817; PMCID: PMC6054564.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCells
    43. Risk factors for progression of and treatment options for NAFLD in children. Clin Liver Dis (Hoboken). 2018 Jan; 11(1):11-15. Hartmann P, Schnabl B. PMID: 29629177; PMCID: PMC5881937.
      View in: PubMed   Mentions: 21  
    44. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017 Jun 30; 127(7):2829-2841. Yang AM, Inamine T, Hochrath K, Chen P, Wang L, Llorente C, Bluemel S, Hartmann P, Xu J, Koyama Y, Kisseleva T, Torralba MG, Moncera K, Beeri K, Chen CS, Freese K, Hellerbrand C, Lee SM, Hoffman HM, Mehal WZ, Garcia-Tsao G, Mutlu EA, Keshavarzian A, Brown GD, Ho SB, Bataller R, Stärkel P, Fouts DE, Schnabl B. PMID: 28530644; PMCID: PMC5490775.
      View in: PubMed   Mentions: 259     Fields:    Translation:HumansAnimalsCells
    45. Tiny RNA with great effects: miR-155 in alcoholic liver disease. J Hepatol. 2016 06; 64(6):1214-6. Hartmann P, Tacke F. PMID: 26948494.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    46. Intestinal REG3 Lectins Protect against Alcoholic Steatohepatitis by Reducing Mucosa-Associated Microbiota and Preventing Bacterial Translocation. Cell Host Microbe. 2016 Feb 10; 19(2):227-39. Wang L, Fouts DE, Stärkel P, Hartmann P, Chen P, Llorente C, DePew J, Moncera K, Ho SB, Brenner DA, Hooper LV, Schnabl B. PMID: 26867181; PMCID: PMC4786170.
      View in: PubMed   Mentions: 205     Fields:    Translation:HumansAnimalsCells
    47. Deficiency of intestinal mucin-2 protects mice from diet-induced fatty liver disease and obesity. Am J Physiol Gastrointest Liver Physiol. 2016 Mar 01; 310(5):G310-22. Hartmann P, Seebauer CT, Mazagova M, Horvath A, Wang L, Llorente C, Varki NM, Brandl K, Ho SB, Schnabl B. PMID: 26702135; PMCID: PMC4773827.
      View in: PubMed   Mentions: 31     Fields:    Translation:Animals
    48. Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res. 2015 May; 39(5):763-75. Hartmann P, Seebauer CT, Schnabl B. PMID: 25872593; PMCID: PMC4402724.
      View in: PubMed   Mentions: 144     Fields:    Translation:HumansAnimals
    49. Methods to determine intestinal permeability and bacterial translocation during liver disease. J Immunol Methods. 2015 Jun; 421:44-53. Wang L, Llorente C, Hartmann P, Yang AM, Chen P, Schnabl B. PMID: 25595554; PMCID: PMC4451427.
      View in: PubMed   Mentions: 128     Fields:    Translation:HumansAnimalsCells
    50. Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. J Hepatol. 2014 Jun; 60(6):1259-67. Wang L, Hartmann P, Haimerl M, Bathena SP, Sjöwall C, Almer S, Alnouti Y, Hofmann AF, Schnabl B. PMID: 24560660; PMCID: PMC4028388.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    51. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology. 2013 Jul; 58(1):108-19. Hartmann P, Chen P, Wang HJ, Wang L, McCole DF, Brandl K, Stärkel P, Belzer C, Hellerbrand C, Tsukamoto H, Ho SB, Schnabl B. PMID: 23408358; PMCID: PMC3695050.
      View in: PubMed   Mentions: 141     Fields:    Translation:HumansAnimals
    52. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol. 2012; 3:402. Hartmann P, Chen WC, Schnabl B. PMID: 23087650; PMCID: PMC3468817.
      View in: PubMed   Mentions: 68  
    53. Toll-like receptor 2-mediated intestinal injury and enteric tumor necrosis factor receptor I contribute to liver fibrosis in mice. Gastroenterology. 2012 Nov; 143(5):1330-1340.e1. Hartmann P, Haimerl M, Mazagova M, Brenner DA, Schnabl B. PMID: 22841787; PMCID: PMC3482543.
      View in: PubMed   Mentions: 73     Fields:    Translation:AnimalsCells
    Phillipp's Networks
    Concepts (155)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (37)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-16-gff1bd585 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California